- CIIX concentrating on multi-pronged growth strategy
- The company operates a top financial-information website, developing CBD initiatives
- CIIX offers investors unique, contemporary ROI opportunities
A fintech enterprise, ChineseInvestors.com Inc. (OTCQB: CIIX) is focusing on its original mission of providing financial information and services to the larger Chinese community in the United States and globally. CIIX has become a leading financial-information website (in Chinese language character sets) for Chinese-speaking investors in the United States and China and continues to pursue new areas for growth in other industries as well (http://cnw.fm/2Rinf).
Via its website, www.ChineseInvestors.com, CIIX offers an array of investor-education products and services. Additionally, the company has recognized exceptional opportunities in the global cannabis industry. Established in 1999, ChineseInvestors.com has its corporate headquarters in San Gabriel, California, with offices in Flushing, New York, and Shanghai, China (http://cnw.fm/IKa0C).
At the heart of CIIX’s financial information and services is its ChineseInvestors Method. This method is an inventive combination of a disciplined investing process, web-based tools, personalized instructions and invaluable support. The company’s investor-education products and services include real-time market commentary and analysis as well as educational-related services. CIIX also offers consultative services to smaller private companies considering becoming a public company and advertising- and public-relations-related support services.
Moreover, CIIX is laying the foundation to leverage the increasing demand for cannabidiol (CBD)-based nutrition and health products through its wholly owned foreign enterprise, CBD Biotech. Part of a burgeoning contemporary trend, the company is working to be a recognized leader in the hemp-based, CBD-oil industry. According to a Jan. 8 Research and Markets article, a minimum of 190 companies in China include industrial cannabis in their business scope (http://cnw.fm/Vs0Hf).
The article also noted that CBD will become the emphasis for the development of the cannabis industry in China in the future. Nonetheless, industrial cannabis is not yet legal for medical applications in China. Consequently, the market is underdeveloped, resulting in low use of industrial cannabis.
The article further explains that as more thorough research is conducted in the field of cannabis, the marketplace for CBD extracts is growing. As that occurs, the application of CBD in food, cosmetics and health products will continue to multiply.
The dynamic CBD industry is a rising market expected to reach $2.1 billion in consumer sales this year. Furthermore, BDS Analytics and Arcview Market Research projects that the collective market for CBD sales in the U.S. will exceed $20 billion by 2024 (http://cnw.fm/a6LKx). BDS Analytics predicts that most CBD product sales will take place in general retail stores instead of cannabis dispensaries.
Astute investors may do well to note how CIIX is well-positioned for growth in this market sector. The company has established a three-year development plan to leverage the merging of CBD and the nutrition with health products market in mainland China. In this marketplace, the benefits of CBD oil have not been broadly recognized.
Based on this wholesale agreement/development plan with a reputable CBD health brand, CIIX initiated the first-ever online, CBD-health products store published in the Chinese language, www.ChineseCBDoil.com. The company sells CBD-infused products both in-store and online. The company’s website caters to an increasing number of Chinese people who are coming to understand the manifold potential health benefits of CBD oil for the treatment of an assortment of conditions, including anxiety, stress, poor sleep, Alzheimer’s disease and other conditions.
ChineseInvestors.com continues to emphasize its two quality revenue channels for sales and profit growth: fintech products and services and CBD programs. Investors may note that in June 2019, the company anticipated the doubling of sales over next 12 months (http://cnw.fm/Heb9W). Also, CIIX is planning an IPO of CBD Biotech early this year. The path ahead looks promising for CIIX along with its visionary management team, customers and investors.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://cnw.fm/CIIX
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
